Article content

Turing Pharmaceuticals CEO Martin Shkreli has been under fire since Sunday for raising a 62-year-old drug’s price from US$13.50 to $750 per pill.

And he hasn’t stayed quiet.

We apologize, but this video has failed to load.

tap here to see other videos from our team. Try refreshing your browser, or Martin Shkreli tried to defend $750 price tag per Daraprim pill on TV and by trolling Twitter — and it backfired Back to video

Turing, a pharmaceutical startup that launched in February, acquired the U.S. marketing rights to the parasitic-infection-fighting drug Daraprim in August.

Almost immediately, Turing jacked up the price of the drug, which is used to prevent malaria and treat toxoplasmosis, a parasitic infection that’s dangerous for pregnant women’s unborn children and for people with weakened immune systems, such as those with AIDS and patients undergoing chemotherapy.

We apologize, but this video has failed to load.

tap here to see other videos from our team. Try refreshing your browser, or

On Tuesday night, the chief executive officer announced that his company would roll back the increase in price, though he didn’t say what the new price might be.

The price hike first drew the attention of medical associations earlier this month and was the focus of a New York Times article published earlier this week. On Twitter Monday, Democratic presidential candidate Hillary Clinton responded to the Times article: